 Tiziana Life Sciences PLC NASDAQ:TLSA said the US Food and Drug Administration FDA has given permission for the enrollment of additional Secondary Progressive Multiple Sclerosis SPMS patients for treatment with intranasal foralumab. The company said its collaborators at the Brigham and Womens Hospital BWH Boston MA have received a Study May Proceed Letter from the FDA to initiate treatment in up to an additional eight SPMS patients as part of an Intermediate-Size Patient Population Expanded Access Investigational New Drug IND. 